← Map · Health Care Equipment · S&P 500
ABT ABBOTT LABORATORIES
No on this lens
1Reach
2Weight
1Proof
4Total / 15
What they are doing
Diversified healthcare. Libre is a quarterly CGM franchise. The 10-K names data-management decision software. The Q2 call was Duo (glucose+ketone sensor), coverage, and pipeline hardware — not an AI discussion. Diagnostics / neuro digital health is strategy language. We are not scoring Abbott as if it were Dexcom.
Why the score
- Reach 1 not 2: decision software is named. No second function we can point to.
- Weight 2 not 3: companion software is table stakes in CGM. Duo is a sensor.
- Proof 1 not 2: is sensor volume. No intelligence result.
What would move it next quarter: A named program in the loop with a result, or an AID pairing Abbott owns.
Open these first
Q2 earnings releaseFord on Libre and Duo — not an AI call
10-KLibre / Lingo decision software is the only intelligence line
Evidence
ABT 10-K (2026-02-20)
FreeStyle Libre system, including sensors, data management decision software; Lingo CGM; Diagnostics digital health solutions; neuromodulation leveraging digital health.
ABT 10-Q (2026-07-28)
No AI / algorithm hits in the quarter 10-Q.
Q2 earnings release
Libre +9.5%, Duo CE mark. No AI narrative.